This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
A recent study by Charles River Associates reveals inequities in access to treatment for multiple sclerosis (MS) across Europe. A summary of key findings, with a link to the full report, can be found at the link below.
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...
The United States is the world leader in innovative drug development, supporting patients and health systems globally by advancing the creation of new cures...
Looking back 10 years, the rare disease space has significantly evolved with a plethora of innovative orphan drug launches and many patients gaining access to...
Tim Wilsdon is speaking during the session. For more information on this event, click here.
